Bap1 Tumor Predisposition Syndrome

BAP1 tumor predisposition syndrome, or: BAP1-TPDS, is associated with an increased risk of "BAP1-inactivated melanocytic tumor" (BIMT; formerly called atypical Spitz tumor), and the following tumor types (in descending order of frequency):

• uveal melanoma (UM)
• malignant mesothelioma (MMe)
• melanoma (of the skin) (CM)
• renal cell carcinoma (RCC)
• basal cell carcinoma (BCC)

Furthermore, the following malignancies may also be associated with BAP1-TPDS:

• Hepatocellular carcinoma
• Cholangiocarcinoma
• meningioma.

Other suspected but unconfirmed tumors in BAP1-TPDS include (in alphabetical order): Breast cancer, urinary bladder cancer, neuroendocrine carcinoma, non-small cell lung adenocarcinoma, thyroid cancer. Affected individuals may have more than one primarius at a time.

BAP1 tumor predisposition syndrome is caused by pathogenic variants in the BAP1 gene . It is inherited in an autosomal dominant manner. BAP1 is a deubiquitylase. It binds to BRCA1 (breast cancer type 1 susceptibility protein) through its RING finger domain and acts as a tumor suppressor. In addition, the enzyme may be involved in the regulation of transcription, cell cycle and growth, DNA damage response and chromatin dynamics.

So far, only point mutations in BAP1 have been described, but the occurrence of deletions or duplications of larger gene segments cannot be excluded.

In general, the median age of onset of these tumors is younger than in the general population.

Criteria for clinical diagnosis have not yet been established, but suspicion exists in patients who meet any of the following:

• at least two confirmed BAP1-associated tumors
• or
• One BAP1-associated tumor and a first- or second-degree relative with a confirmed BAP1-associated tumor (not basal cell carcinoma and/or cutaneous melanoma due to the high frequency in the population).

Consensus recommendations on screening for carriers have not yet been established. However, it is recommended to perform annual check-ups of the eyes and skin with regard to uveal melanomas and skin lesions, respectively. Regarding renal cell carcinoma, screening according to von Hippel-Lindau syndrome can be performed.

If a pathogenic variant has been identified in an affected person, blood relatives can, if they wish, be specifically tested for the variant following genetic counseling (predictive diagnostics). In predictive diagnostics, healthy persons at risk are examined, usually first-degree relatives of affected persons. According to the German Genetic Diagnostics Act (GenDG), genetic counseling should be offered with every diagnostic genetic examination. In the case of predictive genetic diagnostics, the GenDG stipulates that genetic counseling must be provided before the examination and after the results are available (§10, Para. 2 GenDG).

1. Abdel-Rahman MH et al (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma and other cancers. J Med Genet 48:856-859.
2. Abdel-Rahman MH et al (2016) Germline BAP1 mutations misreported as somatic based on tumor-only testing. Fam Cancer. 15:327-330.
3. Aoude LG et al (2015) Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases. Twin Res Hum Genet 18:126-133.
4. Battaglia A (2014) The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol 8:37-47. [
5. Brown A et al (2021) Spitz nevus: review and update. Clin Plast Surg 48:677-686.
6. Carbone M et al (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med10:179.
7. de la Fouchardière A et al (2015) Germline BAP1 mutations also predispose to multiple basal cell carcinomas. Clin Genet 88:273-237.
8. Rai K et al (2017) Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer 56:168-174.